Frostbite‑Induced Neuropathy: Evidence‑Based Management Guidelines

Pharmacologic Management

First‑line oral therapy: Duloxetine 30 mg daily for one week, then 60 mg daily, is recommended as the primary agent for neuropathic pain after severe frostbite. The American Society of Clinical Oncology cites moderate‑quality evidence that benefits balance harms. 1
Second‑line oral agents (if duloxetine fails or is contraindicated): Gabapentin or pregabalin may be used, but evidence outside clinical trials is insufficient for a formal recommendation; a minimum trial of two weeks at therapeutic doses is advised before judging efficacy. 1
Alternative antidepressant: Amitriptyline, initiated at 10–25 mg daily, can provide modest pain relief when first‑line agents are not tolerated; supporting data are limited. 1
Salvage analgesia: Tramadol or strong opioids are reserved for severe, refractory neuropathic pain, drawing on established efficacy in other neuropathic conditions; they should be employed only after failure of other pharmacologic options. 1
Adjunctive NSAID use: Non‑steroidal anti‑inflammatory drugs should not be used as monotherapy for neuropathic pain. Their role is limited to preventing vascular complications (e.g., prostaglandin‑mediated vasoconstriction) rather than analgesia. 1
Therapeutic trial duration: All pharmacologic agents must be administered at appropriate doses for at least two weeks before deeming them ineffective and switching to alternative treatments. 1

Early physical rehabilitation: Initiate coordinated exercise, sensorimotor training, fine‑motor drills, vibration therapy, and balance exercises at the onset of manifest neuropathy to lessen symptom burden; these interventions have demonstrated benefit in neuropathic conditions. 1
Topical menthol: Apply 1 % menthol cream twice daily to the affected region and corresponding dermatome; it yields substantial pain relief with minimal toxicity and low cost, and no adverse events have been reported. 1
Acupuncture: May be offered to selected individuals, though supporting evidence is limited by small sample sizes and short‑term follow‑up. 1

Evidence strength: The recommendation for duloxetine is supported by moderate‑quality evidence; all other pharmacologic and non‑pharmacologic suggestions are based on limited or low‑quality data.
Safety hierarchy: Reserve opioids for refractory cases, avoid NSAIDs or glucocorticoids as sole analgesics, and ensure adequate trial periods for all agents to prevent premature discontinuation.
Comprehensive approach: Effective management must address both neuropathic pain and the underlying vascular dysfunction that perpetuates nerve injury after frostbite.

The American Society of Clinical Oncology recommends duloxetine as first-line pharmacologic therapy for chronic neuropathic pain following severe frostbite, with moderate strength evidence showing benefits equal to harms 2
The American Heart Association suggests that NSAIDs, such as ibuprofen, should be continued long-term to prevent ongoing prostaglandin and thromboxane-mediated vasoconstriction and dermal ischemia 3, 4
Gabapentin/pregabalin may be considered as second-line options for neuropathic pain, though evidence outside clinical trials is insufficient to make formal recommendations 2
Tricyclic antidepressants, such as amitriptyline, may have some benefit for neuropathic pain, though evidence is limited 2

Applying bulky, loose dressings can help protect affected extremities from pressure sores and necrosis 3, 4
Maintaining intact skin barriers can help prevent infection 4

The American Society of Clinical Oncology explicitly states that gabapentin/pregabalin should not be used as first-line therapy for neuropathic pain due to lack of evidence 2
Topical combination gels, such as those containing baclofen, amitriptyline, and ketamine, should be avoided due to lack of evidence for efficacy in neuropathic pain 2